Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

362 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1).
Font A, Mellado B, Climent MA, Virizuela JA, Oudard S, Puente J, Castellano D, González-Del-Alba A, Pinto A, Morales-Barrera R, Rodriguez-Vida A, Fernandez PL, Teixido C, Jares P, Aldecoa I, Gibson N, Solca F, Mondal S, Lorence RM, Serra J, Real FX. Font A, et al. Among authors: real fx. Br J Cancer. 2024 Feb;130(3):434-441. doi: 10.1038/s41416-023-02513-6. Epub 2023 Dec 15. Br J Cancer. 2024. PMID: 38102226 Free PMC article. Clinical Trial.
PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.
Dueñas M, Martínez-Fernández M, García-Escudero R, Villacampa F, Marqués M, Saiz-Ladera C, Duarte J, Martínez V, Gómez MJ, Martín ML, Fernández M, Castellano D, Real FX, Rodriguez-Peralto JL, De La Rosa F, Paramio JM. Dueñas M, et al. Among authors: real fx. Mol Carcinog. 2015 Jul;54(7):566-76. doi: 10.1002/mc.22125. Epub 2013 Dec 18. Mol Carcinog. 2015. PMID: 24347284
CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status.
Rubio C, Martínez-Fernández M, Segovia C, Lodewijk I, Suarez-Cabrera C, Segrelles C, López-Calderón F, Munera-Maravilla E, Santos M, Bernardini A, García-Escudero R, Lorz C, Gómez-Rodriguez MJ, de Velasco G, Otero I, Villacampa F, Guerrero-Ramos F, Ruiz S, de la Rosa F, Domínguez-Rodríguez S, Real FX, Malats N, Castellano D, Dueñas M, Paramio JM. Rubio C, et al. Among authors: real fx. Clin Cancer Res. 2019 Jan 1;25(1):390-402. doi: 10.1158/1078-0432.CCR-18-0685. Epub 2018 Sep 21. Clin Cancer Res. 2019. PMID: 30242024
Immunohistochemistry-Based Taxonomical Classification of Bladder Cancer Predicts Response to Neoadjuvant Chemotherapy.
Font A, Domènech M, Benítez R, Rava M, Marqués M, Ramírez JL, Pineda S, Domínguez-Rodríguez S, Gago JL, Badal J, Carrato C, López H, Quer A, Castellano D, Malats N, Real FX. Font A, et al. Among authors: real fx. Cancers (Basel). 2020 Jul 3;12(7):1784. doi: 10.3390/cancers12071784. Cancers (Basel). 2020. PMID: 32635360 Free PMC article.
Predictive signature of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer integrating mRNA expression, taxonomic subtypes, and clinicopathological features.
Font A, Domenech M, Ramirez JL, Marqués M, Benítez R, Ruiz de Porras V, Gago JL, Carrato C, Sant F, Lopez H, Castellano D, Malats N, Calle ML, Real FX. Font A, et al. Among authors: real fx. Front Oncol. 2023 Aug 3;13:1155244. doi: 10.3389/fonc.2023.1155244. eCollection 2023. Front Oncol. 2023. PMID: 37588099 Free PMC article.
LINE-1 methylation in leukocyte DNA, interaction with phosphatidylethanolamine N-methyltransferase variants and bladder cancer risk.
Tajuddin SM, Amaral AF, Fernández AF, Chanock S, Silverman DT, Tardón A, Carrato A, García-Closas M, Jackson BP, Toraño EG, Márquez M, Urdinguio RG, García-Closas R, Rothman N, Kogevinas M, Real FX, Fraga MF, Malats N; Spanish Bladder Cancer/EPICURO Study investigators. Tajuddin SM, et al. Among authors: real fx. Br J Cancer. 2014 Apr 15;110(8):2123-30. doi: 10.1038/bjc.2014.67. Epub 2014 Mar 4. Br J Cancer. 2014. PMID: 24595004 Free PMC article.
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma.
Hedegaard J, Lamy P, Nordentoft I, Algaba F, Høyer S, Ulhøi BP, Vang S, Reinert T, Hermann GG, Mogensen K, Thomsen MBH, Nielsen MM, Marquez M, Segersten U, Aine M, Höglund M, Birkenkamp-Demtröder K, Fristrup N, Borre M, Hartmann A, Stöhr R, Wach S, Keck B, Seitz AK, Nawroth R, Maurer T, Tulic C, Simic T, Junker K, Horstmann M, Harving N, Petersen AC, Calle ML, Steyerberg EW, Beukers W, van Kessel KEM, Jensen JB, Pedersen JS, Malmström PU, Malats N, Real FX, Zwarthoff EC, Ørntoft TF, Dyrskjøt L. Hedegaard J, et al. Among authors: real fx. Cancer Cell. 2016 Jul 11;30(1):27-42. doi: 10.1016/j.ccell.2016.05.004. Epub 2016 Jun 16. Cancer Cell. 2016. PMID: 27321955 Free article.
Asthma status is associated with decreased risk of aggressive urothelial bladder cancer.
Rava M, Czachorowski MJ, Silverman D, Márquez M, Kishore S, Tardón A, Serra C, García-Closas M, Garcia-Closas R, Carrato A, Rothman N, Real FX, Kogevinas M, Malats N. Rava M, et al. Among authors: real fx. Int J Cancer. 2018 Feb 1;142(3):470-476. doi: 10.1002/ijc.31066. Epub 2017 Oct 16. Int J Cancer. 2018. PMID: 28940228 Free PMC article.
Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors.
Garcia-Carbonero R, Bazan-Peregrino M, Gil-Martín M, Álvarez R, Macarulla T, Riesco-Martinez MC, Verdaguer H, Guillén-Ponce C, Farrera-Sal M, Moreno R, Mato-Berciano A, Maliandi MV, Torres-Manjon S, Costa M, Del Pozo N, Martínez de Villarreal J, Real FX, Vidal N, Capella G, Alemany R, Blasi E, Blasco C, Cascalló M, Salazar R. Garcia-Carbonero R, et al. Among authors: real fx. J Immunother Cancer. 2022 Mar;10(3):e003255. doi: 10.1136/jitc-2021-003255. J Immunother Cancer. 2022. PMID: 35338084 Free PMC article.
362 results